<DOC>
	<DOCNO>NCT00886873</DOCNO>
	<brief_summary>The objective study estimate efficacy safety daily administration 6 month 5 mg versus 10 mg. A 6 month follow-up subject carry estimate effect mifepristone keep time . The hypothesis study mifepristone dose reduce volume myoma 50 % six month treatment .</brief_summary>
	<brief_title>Mifepristone 10 5 mg 6 Months Treat Uterine Fibroids</brief_title>
	<detailed_description>Women , fertile age premenopausal status , present symptomatic myomaswere randomly assign receive 5 10 mg mifepristone six month . The decrease prevalence symptom attributable myomas important goal achieve treatment . Another goal maintain 6 month benefit treatment mifepristone .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>Symptomatic uterine fibroid Reproductive age premenopausal Accepting use non hormonal contraception Conformity keep monthly log episodes vaginal bleeding treatment well side effect mifepristone Agreeing ultrasound examination every followup evaluation visit Agreeing two endometrial biopsy : one start treatment another follow 10 day treatment termination Pregnancy desire become pregnant Breastfeeding Hormonal contraception hormonal therapy receive last three month Signs symptom pelvic inflammatory disease Adnexal mass Abnormal unexplained vaginal bleeding Suspected diagnose malignant neoplastic disease Signs symptoms mental illness Adrenal disease Sickle cell anemia Hepatic disease Renal disease Coagulopathy Any severe important disease Any contraindication receiving antiprogestins</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Uterine fibroid</keyword>
	<keyword>Mifepristone</keyword>
	<keyword>Antiprogestins</keyword>
</DOC>